Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2017 Planned number of patients changed from 205 to 200.
- 23 Oct 2017 Status changed from not yet recruiting to recruiting.